European Breast Cancer Screening Market Forecast to 2027 – COVID-19 Impact and Regional Analysis – ResearchAndMarkets.com

European Breast Cancer Screening Market Forecast to 2027 – COVID-19 Impact and Regional Analysis – ResearchAndMarkets.com




European Breast Cancer Screening Market Forecast to 2027 – COVID-19 Impact and Regional Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Europe Breast Cancer Screening Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Test Type, End User, and Country” report has been added to ResearchAndMarkets.com’s offering.

The European breast cancer screening market was valued at US$ 1,231.82 million in 2019 and is projected to reach US$ 1,586.46 million by 2027; it is expected to grow at CAGR of 4.3% from 2020 to 2027. Increasing incidence of breast cancer and presence of prominent players in the breast cancer screening market, as well as robust research and development activities, are among the prominent factors propelling the market growth. However, the high cost associated with breast cancer screening restrains the growth of the market.

Growing number of breast cancer is mainly due to unhealthy habits, such as smoking, unhealthy diet or infections. As per the Globocan 2019 report, the total number of breast cancer cases in Germany were 71,888 in 2018, and about 19,376 breast cancer deaths were reported. Breast cancer is the most common cancer type in Germany. Additionally, according to Cancer Research UK Statistics there were 55,176 new cases of breast cancer and 11,399 cancer deaths from 2015 to 2017. Many collaborations are made to spread awareness; for instance, Cancer Research UK and Avon Foundation together launched Avon’s Breast Cancer Promise, a multi-year pledge to educate women about breast cancer. This collaboration promises to reach 100 million women each year with vital information about breast cancer. Moreover, the statistics mentioned that nearly 150 new breast cancer cases are diagnosed every day in females. Breast cancer in males is not so common in the UK – as per the cancer research UK there were about 390 new cases in 2017. Furthermore, in Spain, the growing prevalence of breast cancer is likely to demand for screening technologies.

The European breast cancer screening market is segmented into test type and end user. Based on test type, the market is further segmented into imaging test, Immunohistochemistry test, genetic test, and blood marker test. The imaging test segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR during the forecast period. Based on end user, the market is further segmented into hospitals, diagnostic centers, cancer institute’s, and research laboratories. The hospitals segment held the largest share of the market in 2019; moreover, it is expected to register fastest growth during 2020-2027.

Cancer Center Amsterdam, Food and Drug Administration, World Health Organization (WHO), Centers for Disease Control and Prevention, Instituto Nacional de Cancerologia, and International Diabetes Federation area few essential primary and secondary sources referred to for preparing this report.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in The European Breast Cancer Screening Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in The European Breast Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

  • Growing Breast Cancer Cases
  • Growing Initiatives for Breast Cancer Management

Restraints

  • High Cost Associated With Breast Cancer Screening

Opportunities

  • Product Launches Along With The Technological Advancements In Breast Imaging Modalities

Future Trends

  • Growing Agreements And Collaborations For Diagnostic Solutions

Companies Mentioned

  • Koninklijke Philips N.V.
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Myriad Genetics, Inc.
  • Siemens Healthcare AG
  • Exact Sciences Corporation
  • OncoCyte Corporation
  • POC Medical Systems
  • Danaher Corporation
  • General Electric Company

For more information about this report visit https://www.researchandmarkets.com/r/ghmlpa

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900